MSME (Udyam registered) Ministry of MSME
- Category
- Small (2023-24)
- Udyam number
- UDYAM-TS-02-0014898
Curewin-Hylico Pharma Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹9.02 Cr
▲ 10% YoY
Net profit · FY 2025
₹13.66 Lakh
Net margin 1.5%
EBITDA · FY 2025
₹1.23 Cr
EBITDA margin 13.7%
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹4.41 Cr
Issued & subscribed
Open charges
₹1.32 Cr
Satisfied ₹50 Lakh
Company age
12 yrs
Est. 2014
Employees · EPFO
82
Provident fund records
About Curewin-Hylico Pharma Private Limited
Data last updated:
Curewin-Hylico Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 December 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U51101TG2014PTC096702. Its GSTIN is 36AAFCC8618N1Z5 (Telangana). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹4.41 Cr. It is led by directors including Srinivas Lagisetty and Madhavaram Ravinder Rao.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at H No.8 – 2 – 310/B/33 Plot No.33 Ground Floor House No.266 Road No.14 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per the financials filed for FY 2025, the company reported a revenue of ₹9.02 Cr, a growth of 10% compared to the previous year. For the same year it recorded a net profit of ₹13.66 Lakh (net margin 1.5%) and EBITDA of ₹1.23 Cr (EBITDA margin 13.7%). Revenue has grown at a compounded annual rate (CAGR) of 3% over five years.
The company has about 82 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Tata 1mg and Curewin Hylico. As per MCA filings, the company has open charges of ₹1.32 Cr and satisfied charges of ₹50 Lakh on record. Court records list 6 cases involving the company, including 4 filed by the company and 2 filed against it; 3 cases are pending. The company has 5 deals on record (5 funding rounds), with disclosed funding of ₹3.36 Cr; the latest was in May 2019. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (wholesale trading) are compared by revenue, 3 larger and 1 smaller; the largest is A Square Remedies Private Limited with revenue of ₹9.06 Cr.
Curewin-Hylico Pharma Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0014898). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website curewinhylico.com.
Company details
CIN U51101TG2014PTC096702
Registration Number 096702
Incorporation Date 05 December 2014
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-TS-02-0014898
Key People
Srinivas Lagisetty Director Madhavaram Ravinder Rao Director Babu Uttam Kumar Rao Julapalli Director Recognitions & Rankings of Curewin-Hylico Pharma
Contact details
Curewin-Hylico Pharma Private Limited's registered office is in Hyderabad, Telangana. Its website is curewinhylico.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressH No.8 – 2 – 310/B/33 Plot No.33 Ground Floor House No.266 Road No.14 Banjara Hills, Hyderabad, Telangana, India – 500034
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Curewin-Hylico Pharma Private Limited, buy the company report.
Comprehensive company report
Curewin-Hylico Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Curewin-Hylico Pharma operates two associated brands: Tata 1mg and Curewin Hylico. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provider of an online pharmacy with doctor listing and teleconsultation services | 1mg.com | |
| Potato farming, grain marketing, and equipment services associated with Curewin Hylico. | curewinhylico.com |
Business activity
The main business activity of Curewin-Hylico Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Curewin-Hylico Pharma Private Limited, buy the company report.
Financials of Curewin-Hylico Pharma Private Limited
FY 2024 filings availableCurewin-Hylico Pharma Private Limited reported revenue of ₹9.02 Cr (up 10% YoY) for FY 2025.
Revenue · FY 2025
₹9.02 Cr ▲ 10%
Net profit · FY 2025
₹13.66 Lakh margin 1.5%
EBITDA · FY 2025
₹1.23 Cr margin 13.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 10%
5 years · compounded
▲ 3%
EBITDA CAGR growth
1 year
▲ 17%
3 years · compounded
▲ 18%
5 years · compounded
▲ 20%
Revenue has grown at a compounded annual rate (CAGR) of 3% over five years, including 10% growth in the latest year. EBITDA rose 17% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.23 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹13.66 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 13.7% | ||||
| Net Profit Margin | 1.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Curewin-Hylico Pharma Private Limited, buy the company report.
Board of directors of Curewin-Hylico Pharma Private Limited
Curewin-Hylico Pharma has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Srinivas Lagisetty | Director | 05 Dec 2014 | 11 Years 10 Months | Current |
| Madhavaram Ravinder Rao | Director | 28 Apr 2018 | 8 Years 6 Months | Current |
| Babu Uttam Kumar Rao Julapalli Also directs: Tablicaps Pharma Private Limited | Director | 12 Apr 2015 | 11 Years 6 Months | Current |
Peer comparison
Curewin-Hylico Pharma Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| A Square Remedies Private Limited | ₹9.06 Cr (FY 2025) | 23.0% | Ahmedabad, Gujarat, India | |||
| Bennu Bioscience Private Limited | ₹9.03 Cr (FY 2024) | 3294.0% | Delhi, India | |||
| Vzoic Healthcare Private Limited | ₹9.02 Cr (FY 2025) | 3.0% | Chandigarh, India | |||
| Curewin-Hylico Pharma Private Limitedthis company | ₹9.02 Cr (FY 2025) | ₹13.66 Lakh | 1.5% | 10.0% | 82 | Hyderabad, Telangana, India |
| Leo Formulations Private Limited | ₹8.97 Cr (FY 2025) | 4.0% | Sanand, Gujarat, India |
To see the full peer comparison of Curewin-Hylico Pharma Private Limited, buy the company report.
Auditor
Curewin-Hylico Pharma Private Limited is audited by SVSG & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SVSG & CO | FY 2023 | 015268S |
Shareholding
The shareholding of Curewin-Hylico Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Curewin-Hylico Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹1.32 Cr
Satisfied charges
₹50 Lakh
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 21 Dec 2024 | 101022876 | Hdfc Bank Limited | ₹10.2 Lakh | Open | |
| 19 Mar 2022 | 100554590 | Axis Bank Limited | ₹1 Cr | Open | |
| 19 Jan 2022 | 100534993 | Hdfc Bank Limited | ₹21.95 Lakh | Open | |
| 04 Sep 2020 | 100374366 | Hdfc Bank Limited | ₹50 Lakh | Satisfied |
To see the full charge records of Curewin-Hylico Pharma Private Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Curewin-Hylico Pharma Private Limited has 5 deals on record (5 funding rounds), with disclosed funding of ₹3.36 Cr; the latest was in May 2019.
Total deals
5
Funding rounds
5
Disclosed funding
₹3.36 Cr
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2019 | Funding round | ₹31.8 Lakh | Investors: 2 individuals |
| Mar 2019 | Funding round | ₹29 Lakh | Investors: 2 individuals |
| Apr 2018 | Funding round | ₹30 Lakh | Investors: Macro Networking Limited |
| Mar 2018 | Funding round | ₹66.1 Lakh | Investors: Macro Networking Limited , 3 individuals |
| Mar 2016 | Funding round | ₹1.79 Cr | Investors: 4 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Curewin-Hylico Pharma Private Limited has 6 court cases on record: 4 filed by Curewin-Hylico Pharma, 2 filed against it. 3 cases are pending and 3 are disposed.
Total cases
6
Filed by the company
4
Filed against the company
2
Pending
3
Disposed
3
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 2 | 3 |
| Supreme Court | 3 | 0 | 0 |
Cases on record (4 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Indore, Madhya Pradesh | Court case (COMMS) | Filed by the company against Curewin Pharmaceuticals Private Limited Through Virendra Tare | Pending |
| District court, Indore, Madhya Pradesh | Court case (COMMS) | Filed against the company by Curewin Pharmaceuticals Pvt. Ltd. Through Virendra Tare | Pending |
| Supreme Court | Interim or miscellaneous application | Filed by the company against Curewinpharmaceuticals Pvt. Ltd. | Disposed |
| Supreme Court | Court case (Special Leave Petition (Civil)) | Filed by the company against Curewinpharmaceuticals Pvt. Ltd. | Disposed |
To see the full case history of Curewin-Hylico Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Curewin-Hylico Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Curewin-Hylico Pharma Private Limited has a workforce of 82 employees on its EPFO records as of Mar 21, 2024, across 1 active EPFO establishment.
Employee count
82
Active EPFO establishments
1
Employee growth
-2.38%
GST
Curewin-Hylico Pharma has 3 GST registrations: 2 active and 1 cancelled or inactive.
Total GSTINs
3
Active
2
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCC8618N1Z5 | Telangana | Active | 01 Jul 2017 |
| 23AAFCC8618N2ZB | Madhya Pradesh | Active | 10 Dec 2020 |
To see the full GST registrations and return filing status of Curewin-Hylico Pharma Private Limited, buy the company report.
Recent activity
Curewin-Hylico Pharma Private Limited has 8 board changes on record since 2014: 3 appointments and 5 cessations. The latest: Neelesh Rao Julapally ceased to be Director on 07 Feb 2024.
Charges
A charge registered on 04 Sep 2020 via Charge ID 100374366 with Hdfc Bank Limited was fully satisfied on 27 Jan 2025.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.10 Cr with Charge ID 101022876 was registered on 21 Dec 2024.
AGM
Curewin-Hylico Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Curewin-Hylico Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Ceased
Neelesh Rao Julapally ceased to be Director.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.00 Cr with Charge ID 100554590 was registered on 19 Mar 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.22 Cr with Charge ID 100534993 was registered on 19 Jan 2022.
Ceased
Rajendra Tare ceased to be Managing Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.50 Cr with Charge ID 100374366 was registered on 04 Sep 2020.
Ceased
Madhavaram Ravinder Rao ceased to be Additional Director.
Appointed
Madhavaram Ravinder Rao was appointed as Director.
Ceased
Ganjikunta Raju Krishna ceased to be Director.
4 earlier events are in the company report.
Frequently asked questions
Curewin-Hylico Pharma is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 December 2014 (12+ years old) and is registered under CIN U51101TG2014PTC096702.
Curewin-Hylico Pharma has 3 current directors:
- Srinivas Lagisetty - Director
- Madhavaram Ravinder Rao - Director
- Babu Uttam Kumar Rao Julapalli - Director
The latest financial statements of Curewin-Hylico Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Curewin-Hylico Pharma is 36AAFCC8618N1Z5, registered in Telangana. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 23AAFCC8618N2ZB (Madhya Pradesh).
The CIN (Corporate Identification Number) of Curewin-Hylico Pharma is U51101TG2014PTC096702. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Curewin-Hylico Pharma has 6 court cases on record: 4 filed by the company and 2 filed against it. 3 are pending. Most are in the district courts.
Curewin-Hylico Pharma was incorporated on 05 December 2014, making it 12+ years old. It is registered with the Registrar of Companies, Hyderabad.
Curewin-Hylico Pharma has 5 deals on record (5 funding rounds), with disclosed funding of ₹3.36 Cr; the latest was in May 2019.
The peers of Curewin-Hylico Pharma by revenue are A Square Remedies Private Limited, Bennu Bioscience Private Limited, Vzoic Healthcare Private Limited, Leo Formulations Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (wholesale trading).
Neelesh Rao Julapally ceased to be Director on 07 Feb 2024. Rajendra Tare ceased to be Managing Director on 25 Sep 2020. Madhavaram Ravinder Rao ceased to be Additional Director on 29 Sep 2018. Curewin-Hylico Pharma has 8 board changes on record in total.
Yes, Curewin-Hylico Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-TS-02-0014898).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages